[Inhibitory effect of ardipusilloside-I on Lewis pulmonary carcinoma and hepatocarcinoma SMMC-7721].
To study the antitumor effect of ardipusilloside-I (ADS-I) on Lewis pulmonary carcinoma and hepatocarcinoma SMMC-7721. Lewis pulmonary metastasizing model was made by Sc. diluted 3-time 20 microl cancer cells in the right sole of C57BL/6 mice, after we treated the mice 14 days with ADS-I orally, cut the neoplasia-foot and weighed, we calculated the inhibitory rate in situ, then put the mice to death after being administrated 11 days continuously, counted the lung medtastasis colony and calculated the metastasis inhibitory rate; Human being hepatocarcinoma model was made by sc. in the back 5 x 10(6)/ml SMMC-7721 cells per BALB/c/nu nude mice, after we treated them orally 16 days with ADS-I continuously, measured the volume of tumor growth and body weight, and drew the growth curve, we detached the tumor and calculated the inhibitory rate of tumor growth in the end. Lewis pulmonary carcinoma inhibitory rate in situ and lung transfer inhibitory rate of ADS-I (25 mg/kg - 100 mg/kg) were between 40.5% and 54.0%, 45.4% and 69.1% respectively; Inhibitory rate of hepatocarcinoma SMMC-7721 was between 45.6% and 56.3%. ADS-I has inhibitory effect on Lewis pulmonary metastasis carcinoma and hepatocarcinoma SMMC-7721 carcinoma.